[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA02012708A - Moduladores ppar-gamma de quinolinilo y benzotiazolilo. - Google Patents

Moduladores ppar-gamma de quinolinilo y benzotiazolilo.

Info

Publication number
MXPA02012708A
MXPA02012708A MXPA02012708A MXPA02012708A MXPA02012708A MX PA02012708 A MXPA02012708 A MX PA02012708A MX PA02012708 A MXPA02012708 A MX PA02012708A MX PA02012708 A MXPA02012708 A MX PA02012708A MX PA02012708 A MXPA02012708 A MX PA02012708A
Authority
MX
Mexico
Prior art keywords
benzothiazolyl
quinolinyl
ppar
substituted
unsubstituted
Prior art date
Application number
MXPA02012708A
Other languages
English (en)
Inventor
Jonathan B Houze
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of MXPA02012708A publication Critical patent/MXPA02012708A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Quinoline Compounds (AREA)
  • Holo Graphy (AREA)
MXPA02012708A 2000-06-28 2001-06-27 Moduladores ppar-gamma de quinolinilo y benzotiazolilo. MXPA02012708A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21481000P 2000-06-28 2000-06-28
PCT/US2001/020756 WO2002000633A1 (en) 2000-06-28 2001-06-27 Quinolinyl and benzothiazolyl ppar-gamma modulators

Publications (1)

Publication Number Publication Date
MXPA02012708A true MXPA02012708A (es) 2003-09-22

Family

ID=22800496

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012708A MXPA02012708A (es) 2000-06-28 2001-06-27 Moduladores ppar-gamma de quinolinilo y benzotiazolilo.

Country Status (25)

Country Link
EP (1) EP1296967B1 (es)
JP (1) JP4515026B2 (es)
KR (1) KR100771286B1 (es)
CN (1) CN1243741C (es)
AT (1) ATE327984T1 (es)
AU (2) AU2001271637B2 (es)
BR (1) BRPI0112115B8 (es)
CA (1) CA2412723C (es)
CY (1) CY1105126T1 (es)
CZ (1) CZ302982B6 (es)
DE (1) DE60120163T2 (es)
DK (1) DK1296967T3 (es)
EA (1) EA005976B1 (es)
ES (1) ES2265435T3 (es)
HK (1) HK1052351B (es)
HU (1) HUP0301482A3 (es)
IL (2) IL153461A0 (es)
MX (1) MXPA02012708A (es)
NO (1) NO325448B1 (es)
NZ (1) NZ523229A (es)
PL (1) PL214670B1 (es)
PT (1) PT1296967E (es)
SK (1) SK288236B6 (es)
WO (1) WO2002000633A1 (es)
ZA (1) ZA200210283B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
CN1585638A (zh) 2001-09-14 2005-02-23 图拉里克公司 被连接的联芳基化合物
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US7238717B2 (en) 2002-05-24 2007-07-03 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
PT1798223E (pt) 2002-11-18 2011-10-17 Chemocentryx Inc Aril-sulfonamidas
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MXPA05008600A (es) 2003-02-13 2005-11-04 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CA2521189A1 (en) * 2003-04-11 2004-10-28 Gabor Tigyi Lysophosphatidic acid analogs and inhibition of neointima formation
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US7544702B2 (en) 2004-08-12 2009-06-09 Amgen Inc. Bisaryl-sulfonamides
WO2007087504A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007087505A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20090176885A1 (en) 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007095601A2 (en) * 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
BRPI0718510A2 (pt) * 2006-09-21 2013-11-19 Piramal Life Sciences Ltd Derivados de 3-amino piridina para o tratamento de desordens metabólicas
WO2012162463A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation
SG10202103552XA (en) 2015-03-09 2021-05-28 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
CN109651208B (zh) * 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物,其药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
ATE413386T1 (de) * 1998-01-29 2008-11-15 Amgen Inc Ppar-gamma modulatoren
SG148834A1 (en) * 1999-06-30 2009-01-29 Japan Tobacco Inc Compounds for the modulation of ppary activity

Also Published As

Publication number Publication date
BR0112115A (pt) 2003-04-29
JP2004501905A (ja) 2004-01-22
CN1438998A (zh) 2003-08-27
EA005976B1 (ru) 2005-08-25
ZA200210283B (en) 2005-09-28
BRPI0112115B1 (pt) 2016-07-26
JP4515026B2 (ja) 2010-07-28
EP1296967A1 (en) 2003-04-02
HUP0301482A2 (hu) 2003-09-29
KR20030024713A (ko) 2003-03-26
NO20026156L (no) 2003-02-25
IL153461A (en) 2007-10-31
DE60120163D1 (de) 2006-07-06
ATE327984T1 (de) 2006-06-15
EA200300078A1 (ru) 2003-08-28
PL359996A1 (en) 2004-09-06
CY1105126T1 (el) 2010-03-03
HUP0301482A3 (en) 2005-12-28
CA2412723C (en) 2010-12-14
SK288236B6 (sk) 2015-01-07
HK1052351B (zh) 2006-11-03
DE60120163T2 (de) 2007-04-12
NZ523229A (en) 2004-10-29
CA2412723A1 (en) 2002-01-03
PL214670B1 (pl) 2013-08-30
PT1296967E (pt) 2006-10-31
AU7163701A (en) 2002-01-08
IL153461A0 (en) 2003-07-06
DK1296967T3 (da) 2006-10-02
AU2001271637B2 (en) 2006-05-04
WO2002000633A1 (en) 2002-01-03
EP1296967B1 (en) 2006-05-31
BRPI0112115B8 (pt) 2021-05-25
KR100771286B1 (ko) 2007-10-29
NO325448B1 (no) 2008-05-05
ES2265435T3 (es) 2007-02-16
CN1243741C (zh) 2006-03-01
HK1052351A1 (en) 2003-09-11
CZ302982B6 (cs) 2012-02-01
CZ20024197A3 (cs) 2003-06-18
SK18352002A3 (sk) 2003-04-01
NO20026156D0 (no) 2002-12-20

Similar Documents

Publication Publication Date Title
AU7163701A (en) Quinolinyl and benzothiazolyl ppar-gamma modulators
PL340451A1 (en) Safe information transfer form revealing any attempts of manipulations by unauthorised persons
FI861995A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(4-benzoyl-1-piperidinyl)-1 -fenylalkanolderivat.
TR200201613T2 (tr) Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler
NO20000282L (no) Dispersjon av titanpartikler omfattende et bindemiddel basert põ et polyorganosiloksan
NO991686L (no) Anvendelse av sarkosinater som asfaltendispergatorer
IL106469A0 (en) Novel pyridyl-and pyrimidylpiperazine derivatives
HUP0400474A2 (hu) Klórozott pirimidinek előállítása
AU569326B2 (en) 2-(n-pyrrolidino)-3-isobutoxy-n-substituted phenyl-n-benzyl-propylamines
DE69706355D1 (de) Alkylendiamin-Derivate als Arzneimittel zur Behandlung von Geschwüren und Hemmung von Helicobacter pylori
DE59509850D1 (de) Verwendung weissgetönter kunststoffe zum weisstönen von papierstreichmassen und derart weissgetönte papierstreichmassen
FI915025A (fi) 8-azabicyklo(3,2,1) oktylalkyltiazolidinoner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
EP1001123A3 (de) Tür- oder Fensterband
GR75012B (es)
GB0116526D0 (en) Window opening mechanism
FR2710680B3 (fr) Dispositif électronique de surveillance et d'alarme pour la maintenance des ressorts à gaz assurant la compensation des portes basculantes.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status